Your shopping cart is currently empty

CPL207280, an orally active GPR40/FFA1 agonist with antidiabetic effects, enhances glucose-stimulated insulin secretion and improves glucose tolerance in MIN6 pancreatic β-cells, healthy Wistar Han rats, and diabetic rat models, making it a valuable compound for type 2 diabetes research [1] [2].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | CPL207280, an orally active GPR40/FFA1 agonist with antidiabetic effects, enhances glucose-stimulated insulin secretion and improves glucose tolerance in MIN6 pancreatic β-cells, healthy Wistar Han rats, and diabetic rat models, making it a valuable compound for type 2 diabetes research [1] [2]. |
| In vivo | CPL207280, administered as a single oral dose of 10 mg/kg, exhibits hypoglycemic effects in Wistar Han rats. Its pharmacokinetic parameters at a 3 mg/kg oral dose include a Cmax of 1699 ng/mL, Tmax of 1 hour, and T1/2 of 1.41 hours [1]. |
| Molecular Weight | 286.37 |
| Formula | C18H22O3 |
| Cas No. | 2361497-72-3 |
| Smiles | [C@@H](CC(O)=O)(C#CC)C1=CC=C(OCC(=C(C)C)C)C=C1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.